Range Nuclear Renaissance ETF vs Summit Therapeutics Inc — how do they compare? Range Nuclear Renaissance ETF trades at $61.06 (market cap $698.21M), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 19.6× Range Nuclear Renaissance ETF's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Range Nuclear Renaissance ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Range Nuclear Renaissance ETF for 18 Days and Summit Therapeutics Inc for 16 Days on average.
| NUKZ | SMMT | |
|---|---|---|
Market Cap | $698.21M | $13.71B |
Volume | 57,444 | 6,173,057 |
Sector | Sector/Thematic | Health |
52-Week High | $76.23 | $26.38 |
52-Week Low | $60.23 | $12.43 |
Typical Hold Time | 18 Days | 16 Days |
Enterprise Value | — | $13.04B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Trailing returns across standard periods
Latest headlines on both assets
Range Nuclear Renaissance ETF seeks to track companies related to the nuclear energy industry. Its holdings may include businesses involved in uranium, nuclear power generation, reactors, and nuclear services.
Read more on NUKZ →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →